Endothelin inhibitors for advanced prostate cancer
Citation:Foley R, Keane J, O Mathuna DP, Hollywood D., Endothelin inhibitors for advanced prostate cancer, Cochrane Database of Systematic Reviews, 8, CD009193, 2011
Endothelin inhibitors for advanced prostate cancer (Protocol).pdf (Published (publisher's copy) - Peer Reviewed) 157.7Kb
This is the protocol for a review and there is no abstract. The objectives are as follows: Our review aims to determine the effectiveness and adverse effects of endothelin inhibitors for advanced prostate cancer. The primary objectives are to assess the effect of endothelin inhibitors on overall survival, prostate cancer-speci?c survival, and progression-free survival. The secondary objectives are to determine: 1. the frequency of adverse events; 2. the effect of treatment on target lesions identi?ed by radiological imaging; 3. the effect of treatment on molecular biomarkers, including PSA and bone alkaline phosphatase; 4. the impact on quality of life.
Health Research Board
Type of material:Journal Article
Series/Report no:Cochrane Database of Systematic Reviews;
Availability:Full text available